Entry - #219500 - CYSTATHIONINURIA - OMIM - (MIRROR)

# 219500

CYSTATHIONINURIA


Alternative titles; symbols

CYSTATHIONASE DEFICIENCY


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
1p31.1 Cystathioninuria 219500 AR 3 CTH 607657
Clinical Synopsis
 

INHERITANCE
- Autosomal recessive
LABORATORY ABNORMALITIES
- Hepatic gamma-cystathionase deficiency
- Cystathioninuria
MISCELLANEOUS
- Majority of patients are pyridoxine-responsive
MOLECULAR BASIS
- Caused by mutations in the cystathionase gene (CTH, 607657.0001)

TEXT

A number sign (#) is used with this entry because cystathioninuria is caused by homozygous or compound heterozygous mutation in the gene encoding cystathionine gamma-lyase (CTH; 607657) on chromosome 1p31.


Description

Cystathioninuria, an autosomal recessive phenotype with no striking pathologic features, is characterized by abnormal accumulation of plasma cystathionine, leading to increased urinary excretion. Because of the inconsistency and wide variety of disease associations, cystathioninuria is considered to be a benign biochemical anomaly (Mudd et al., 2001).


Clinical Features

During a survey by paper chromatography of amino acids in the urine of patients in a mental hospital, Harris et al. (1959) discovered a patient with abnormal excretion of cystathionine. An inborn error involving the cleavage of cystathionine to give cysteine and homoserine was suggested. The patient was a 64-year-old woman with severe mental retardation who had been in the hospital for more than 50 years. However, the metabolic disorder may have been fortuitously associated with mental retardation. Another case was studied at The New York Hospital. Other clinical manifestations have been clubfoot, developmental defects about the ears, convulsions, and thrombocytopenia. Urinary lithiasis also occurs.

Mongeau et al. (1966) described the case of a 2-year-old boy with normal mentality, thrombocytopenia, and urinary calculi. The relation of the latter 2 features to the metabolic defect was problematic. Both parents (who were apparently unrelated) showed cystathioninuria after methionine loading test. With administration of pyridoxine, cystathioninuria was diminished in the proband.

Schneiderman (1967) studied 2 brothers with mental retardation who excreted large amounts of cystathionine after methionine ingestion. The mother and another brother excreted lesser but abnormal amounts after methionine loading. The father was not tested.

Perry et al. (1968) discovered cystathioninuria in a brother and sister when the brother's urine was by chance subjected to 2-dimensional paper chromatography for amino acids. Both children were normal. The parents excreted cystathionine only after methionine loading. The authors suggested that mental defect and other disorders reported in association with cystathioninuria may have been coincidental. Whelan and Scriver (1968) also found cystathioninuria as an apparently benign inborn error.

Observations of cystinuria in connection with neuroblastoma (Klein et al., 1988) may derive from a secondary effect of the tumor process. Among cases of primary cystathioninuria, there are biochemical differences, such as variable response to methionine loading and/or B-vitamin treatment, suggesting the possibility of molecular genetic heterogeneity (Pascal et al., 1978; Tada et al., 1968).

Espinos et al. (2010) reported 3 unrelated Spanish girls with cystathioninuria. They were investigated because of neurologic problems, and the relationship between the cystathioninuria and clinical abnormalities may have been due to ascertainment bias. Two girls had mental retardation, 1 with seizures, and 1 had normal intelligence but showed tremor. All had increased urinary cystathionine at the time of the study. Two had mildly increased plasma homocysteine. Oral pyridoxine treatment normalized the biochemical parameters, but resulted in only partial clinical improvement in the 2 mildly affected individuals. None of the patients had sibs, and all parents were unaffected.


Biochemical Features

Perry et al. (1968) discovered cystathioninuria in a brother and sister when the brother's urine was by chance subjected to 2-dimensional paper chromatography for amino acids. Both children were normal. The parents excreted cystathionine only after methionine loading. The authors suggested that mental defect and other disorders reported in association with cystathioninuria may have been coincidental. Whelan and Scriver (1968) also found cystathioninuria as an apparently benign inborn error.

In 2 of 3 unrelated Spanish girls with cystathioninuria, Espinos et al. (2010) observed mildly increased plasma homocysteine. One girl had severe psychomotor retardation, another had mild mental retardation, 'clinically partial seizures,' and EEG generalized spikes, and the third had postural and action tremor and normal intelligence. Oral pyridoxine treatment normalized the biochemical parameters, but resulted in only partial clinical improvement in the 2 mildly affected individuals.


Inheritance

The transmission pattern of cystathioninuria in the families reported by Tadiboyina et al. (2005) was consistent with autosomal recessive inheritance.


Pathogenesis

Frimpter (1965) showed that the defect involves cystathionase that does not properly bind its coenzyme, pyridoxal phosphate. In vitro studies suggested that high pyridoxine would be therapeutically beneficial.


Population Genetics

Screening surveys of neonatal urine samples have estimated the prevalence of cystathioninuria at 1 per 14,000 live births (Wong et al., 1979), with somewhat lower incidence in other reports (Wilcken et al., 1980; Lemieux et al., 1988).


Molecular Genetics

From genomic DNA, Wang and Hegele (2003) sequenced the CTH gene in 4 unrelated probands with cystathioninuria. They found 2 nonsense and 2 missense mutations (607657.0001-607657.0004). All affected subjects were either homozygotes or compound heterozygotes.

Tadiboyina et al. (2005) reported 3 patients from 2 apparently unrelated Old Colony Mennonite families, each of whom had the hepatocerebral form of mitochondrial DNA depletion syndrome (251880) together with cystathioninuria. All 3 children were homozygous for a missense mutation (601465.0007) in the DGUOK gene, for which the parents were heterozygous, but no mutations were identified in the CTH gene in any subject. Tadiboyina et al. (2005) suggested that the hepatocerebral form of mtDNA depletion syndrome might be associated with secondary cystathioninuria.

Espinos et al. (2010) identified a homozygous mutation in the CTH gene (T67I; 607657.0003) in 3 unrelated Spanish girls with cystathioninuria. Haplotype analysis of these 3 patients and of 2 Czech patients with the mutation suggested a founder effect, and the mutation was estimated to be 7,336 years (262 generations) old. The event may have occurred during the spread of the European population in the Neolithic era. Espinos et al. (2010) noted that T67I, which is the most common change in the CTH gene and has been observed in heterozygous state in 1.5% of controls in the Czech population, has been considered a polymorphism (rs28941785).


Animal Model

Ishii et al. (2010) found that Cth-null mice mice developed normally and did not show hypertension. Both male and female mutant mice showed hypercystathioninemia and hyperhomocysteinemia, but not hypermethioninemia. Ishii et al. (2010) also found that Cth-null mice developed acute skeletal muscle atrophy and myopathy resulting in severe paralysis and death when fed a low cysteine diet. Both Cth-null mice and hepatocytes derived from these mice showed increased vulnerability to oxidative injury. Glutathione levels were reduced in liver and skeletal muscle. The findings indicated that cysteine is an essential amino acid in Cth-null mice. Ishii et al. (2010) postulated that the severe myopathy in Cth-null mice may be present in unknown cases of human CTH deficiency, and noted that these patients may have hyperhomocysteinemia, which may be an independent risk factor for disease.


REFERENCES

  1. Espinos, C., Garcia-Cazorla, A., Martinez-Rubio, D., Martinez-Martinez, E., Vilaseca, M. A., Perez-Duenas, B., Kozich, V., Palau, F., Artuch, R. Ancient origin of the CTH alelle (sic) carrying the c.200C-T (p.T67I) variant in patients with cystathioninuria. Clin. Genet. 78: 554-559, 2010. [PubMed: 20584029, related citations] [Full Text]

  2. Frimpter, G. W., Haymovitz, A., Horwith, M. Cystathioninuria. New Eng. J. Med. 268: 333-339, 1963. [PubMed: 13959884, related citations] [Full Text]

  3. Frimpter, G. W. Cystathioninuria: nature of the defect. Science 149: 1095-1096, 1965. [PubMed: 5826521, related citations] [Full Text]

  4. Harris, H., Penrose, L. S., Thomas, D. H. H. Cystathioninuria. Ann. Hum. Genet. 23: 442-453, 1959. [PubMed: 14399948, related citations] [Full Text]

  5. Ishii, I., Akahoshi, N., Yamada, H., Nakano, S., Izumi, T., Suematsu, M. Cystathionine gamma-Lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury. J. Biol. Chem. 285: 26358-26368, 2010. [PubMed: 20566639, images, related citations] [Full Text]

  6. Klein, C. E., Roberts, B., Holcenberg, J., Glode, L. M. Cystathionine metabolism in neuroblastoma. Cancer 62: 291-298, 1988. [PubMed: 3383129, related citations] [Full Text]

  7. Lemieux, B., Auray-Blais, C., Giguere, R., Shapcott, D., Scriver, C. R. Newborn urine screening experience with over one million infants in the Quebec network of genetic medicine. J. Inherit. Metab. Dis. 11: 45-55, 1988. [PubMed: 3128688, related citations] [Full Text]

  8. Lyon, I. C. T., Procopis, P. G., Turner, B. Cystathioninuria in a well baby population. Acta Paediat. Scand. 60: 324-328, 1971. [PubMed: 5579857, related citations] [Full Text]

  9. Mongeau, J.-G., Hilgartner, M., Worthen, H. G., Frimpter, G. W. Cystathioninuria: study of an infant with normal mentality, thrombocytopenia, and renal calculi. J. Pediat. 69: 1113-1120, 1966. [PubMed: 5951293, related citations] [Full Text]

  10. Mudd, S. H., Levy, H. L., Kraus, J. P. Disorders of Transsulfuration. In: Scriver, C. R.; Beaudet, A. L.; Sly, W. S.; Valle, D. (eds.): The Metabolic and Molecular Bases of Inherited Disease. Vol. II. (8th ed.) New York: McGraw-Hill (pub.) 2001. Pp. 2040-2043.

  11. Pascal, T. A., Gaull, G. E., Beratis, N. G., Gillam, B. M., Tallan, H. H. Cystathionase deficiency: evidence for genetic heterogeneity in primary cystathioninuria. Pediat. Res. 12: 125-133, 1978. [PubMed: 417288, related citations] [Full Text]

  12. Perry, T. L., Hardwick, D. F., Hansen, S., Love, D. L., Israels, S. Cystathioninuria in two healthy siblings. New Eng. J. Med. 278: 590-592, 1968. [PubMed: 5637757, related citations] [Full Text]

  13. Schneiderman, L. J. Latent cystathioninuria. J. Med. Genet. 4: 260-263, 1967. [PubMed: 6082903, related citations] [Full Text]

  14. Scott, C. R., Dassell, S. W., Clark, S. H., Chiang-Teng, C., Swedberg, K. R. Cystathioninemia: a benign genetic condition. J. Pediat. 76: 571-577, 1970. [PubMed: 5420794, related citations] [Full Text]

  15. Shaw, K. N. F., Lieberman, E., Koch, R., Donnell, G. N. Cystathioninuria. Am. J. Dis. Child. 113: 119-128, 1967. [PubMed: 4289134, related citations] [Full Text]

  16. Tada, K., Yoshida, T., Yokoyama, Y., Sato, T., Nakagawa, H., Arakawa, T. Cystathioninuria not associated with vitamin B6 dependency: a probably new type of cystathioninuria. Tohoku J. Exp. Med. 95: 235-242, 1968. [PubMed: 5707897, related citations] [Full Text]

  17. Tadiboyina, V. T., Rupar, A., Atkison, P. Feigenbaum, A., Kronick, J., Wang, J., Hegele, R. A. Novel mutation in DGUOK in hepatocerebral mitochondrial DNA depletion syndrome associated with cystathioninuria. Am. J. Med. Genet. 135A: 289-291, 2005. [PubMed: 15887277, related citations] [Full Text]

  18. Wang, J., Hegele, R. A. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). Hum. Genet. 112: 404-408, 2003. [PubMed: 12574942, related citations] [Full Text]

  19. Whelan, D. T., Scriver, C. R. Cystathioninuria and renal iminoglycinuria in a pedigree: a perspective on counseling. New Eng. J. Med. 278: 924-927, 1968. [PubMed: 5644557, related citations] [Full Text]

  20. Wilcken, B., Smith, A., Brown, D. A. Urine screening for aminoacidopathies: is it beneficial? Results of a long-term follow-up of cases detected by screening one million babies. J. Pediat. 97: 492-497, 1980. [PubMed: 7411317, related citations] [Full Text]

  21. Wong, L. T., Hardwick, D. F., Applegarth, D. A., Davidson, A. G. Review of metabolic screening program of Children's Hospital, Vancouver, British Columbia. Clin. Biochem. 12: 167-172, 1979. [PubMed: 519848, related citations] [Full Text]


Cassandra L. Kniffin - updated : 5/17/2012
Cassandra L. Kniffin - updated : 10/22/2010
Marla J. F. O'Neill - updated : 7/12/2005
Victor A. McKusick - updated : 3/25/2003
Creation Date:
Victor A. McKusick : 6/3/1986
carol : 10/28/2024
carol : 10/24/2024
alopez : 07/13/2023
carol : 08/12/2020
carol : 09/09/2016
carol : 07/09/2016
carol : 5/29/2014
terry : 5/18/2012
carol : 5/17/2012
ckniffin : 5/17/2012
wwang : 11/1/2010
ckniffin : 10/22/2010
wwang : 7/18/2005
terry : 7/12/2005
terry : 7/12/2005
terry : 5/16/2003
carol : 3/27/2003
tkritzer : 3/26/2003
terry : 3/25/2003
carol : 9/22/1999
davew : 8/26/1994
mimadm : 2/19/1994
carol : 2/4/1993
supermim : 3/16/1992
supermim : 3/20/1990
ddp : 10/26/1989

# 219500

CYSTATHIONINURIA


Alternative titles; symbols

CYSTATHIONASE DEFICIENCY


SNOMEDCT: 13003007;   ICD10CM: E72.19;   ORPHA: 212;   DO: 0090142;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
1p31.1 Cystathioninuria 219500 Autosomal recessive 3 CTH 607657

TEXT

A number sign (#) is used with this entry because cystathioninuria is caused by homozygous or compound heterozygous mutation in the gene encoding cystathionine gamma-lyase (CTH; 607657) on chromosome 1p31.


Description

Cystathioninuria, an autosomal recessive phenotype with no striking pathologic features, is characterized by abnormal accumulation of plasma cystathionine, leading to increased urinary excretion. Because of the inconsistency and wide variety of disease associations, cystathioninuria is considered to be a benign biochemical anomaly (Mudd et al., 2001).


Clinical Features

During a survey by paper chromatography of amino acids in the urine of patients in a mental hospital, Harris et al. (1959) discovered a patient with abnormal excretion of cystathionine. An inborn error involving the cleavage of cystathionine to give cysteine and homoserine was suggested. The patient was a 64-year-old woman with severe mental retardation who had been in the hospital for more than 50 years. However, the metabolic disorder may have been fortuitously associated with mental retardation. Another case was studied at The New York Hospital. Other clinical manifestations have been clubfoot, developmental defects about the ears, convulsions, and thrombocytopenia. Urinary lithiasis also occurs.

Mongeau et al. (1966) described the case of a 2-year-old boy with normal mentality, thrombocytopenia, and urinary calculi. The relation of the latter 2 features to the metabolic defect was problematic. Both parents (who were apparently unrelated) showed cystathioninuria after methionine loading test. With administration of pyridoxine, cystathioninuria was diminished in the proband.

Schneiderman (1967) studied 2 brothers with mental retardation who excreted large amounts of cystathionine after methionine ingestion. The mother and another brother excreted lesser but abnormal amounts after methionine loading. The father was not tested.

Perry et al. (1968) discovered cystathioninuria in a brother and sister when the brother's urine was by chance subjected to 2-dimensional paper chromatography for amino acids. Both children were normal. The parents excreted cystathionine only after methionine loading. The authors suggested that mental defect and other disorders reported in association with cystathioninuria may have been coincidental. Whelan and Scriver (1968) also found cystathioninuria as an apparently benign inborn error.

Observations of cystinuria in connection with neuroblastoma (Klein et al., 1988) may derive from a secondary effect of the tumor process. Among cases of primary cystathioninuria, there are biochemical differences, such as variable response to methionine loading and/or B-vitamin treatment, suggesting the possibility of molecular genetic heterogeneity (Pascal et al., 1978; Tada et al., 1968).

Espinos et al. (2010) reported 3 unrelated Spanish girls with cystathioninuria. They were investigated because of neurologic problems, and the relationship between the cystathioninuria and clinical abnormalities may have been due to ascertainment bias. Two girls had mental retardation, 1 with seizures, and 1 had normal intelligence but showed tremor. All had increased urinary cystathionine at the time of the study. Two had mildly increased plasma homocysteine. Oral pyridoxine treatment normalized the biochemical parameters, but resulted in only partial clinical improvement in the 2 mildly affected individuals. None of the patients had sibs, and all parents were unaffected.


Biochemical Features

Perry et al. (1968) discovered cystathioninuria in a brother and sister when the brother's urine was by chance subjected to 2-dimensional paper chromatography for amino acids. Both children were normal. The parents excreted cystathionine only after methionine loading. The authors suggested that mental defect and other disorders reported in association with cystathioninuria may have been coincidental. Whelan and Scriver (1968) also found cystathioninuria as an apparently benign inborn error.

In 2 of 3 unrelated Spanish girls with cystathioninuria, Espinos et al. (2010) observed mildly increased plasma homocysteine. One girl had severe psychomotor retardation, another had mild mental retardation, 'clinically partial seizures,' and EEG generalized spikes, and the third had postural and action tremor and normal intelligence. Oral pyridoxine treatment normalized the biochemical parameters, but resulted in only partial clinical improvement in the 2 mildly affected individuals.


Inheritance

The transmission pattern of cystathioninuria in the families reported by Tadiboyina et al. (2005) was consistent with autosomal recessive inheritance.


Pathogenesis

Frimpter (1965) showed that the defect involves cystathionase that does not properly bind its coenzyme, pyridoxal phosphate. In vitro studies suggested that high pyridoxine would be therapeutically beneficial.


Population Genetics

Screening surveys of neonatal urine samples have estimated the prevalence of cystathioninuria at 1 per 14,000 live births (Wong et al., 1979), with somewhat lower incidence in other reports (Wilcken et al., 1980; Lemieux et al., 1988).


Molecular Genetics

From genomic DNA, Wang and Hegele (2003) sequenced the CTH gene in 4 unrelated probands with cystathioninuria. They found 2 nonsense and 2 missense mutations (607657.0001-607657.0004). All affected subjects were either homozygotes or compound heterozygotes.

Tadiboyina et al. (2005) reported 3 patients from 2 apparently unrelated Old Colony Mennonite families, each of whom had the hepatocerebral form of mitochondrial DNA depletion syndrome (251880) together with cystathioninuria. All 3 children were homozygous for a missense mutation (601465.0007) in the DGUOK gene, for which the parents were heterozygous, but no mutations were identified in the CTH gene in any subject. Tadiboyina et al. (2005) suggested that the hepatocerebral form of mtDNA depletion syndrome might be associated with secondary cystathioninuria.

Espinos et al. (2010) identified a homozygous mutation in the CTH gene (T67I; 607657.0003) in 3 unrelated Spanish girls with cystathioninuria. Haplotype analysis of these 3 patients and of 2 Czech patients with the mutation suggested a founder effect, and the mutation was estimated to be 7,336 years (262 generations) old. The event may have occurred during the spread of the European population in the Neolithic era. Espinos et al. (2010) noted that T67I, which is the most common change in the CTH gene and has been observed in heterozygous state in 1.5% of controls in the Czech population, has been considered a polymorphism (rs28941785).


Animal Model

Ishii et al. (2010) found that Cth-null mice mice developed normally and did not show hypertension. Both male and female mutant mice showed hypercystathioninemia and hyperhomocysteinemia, but not hypermethioninemia. Ishii et al. (2010) also found that Cth-null mice developed acute skeletal muscle atrophy and myopathy resulting in severe paralysis and death when fed a low cysteine diet. Both Cth-null mice and hepatocytes derived from these mice showed increased vulnerability to oxidative injury. Glutathione levels were reduced in liver and skeletal muscle. The findings indicated that cysteine is an essential amino acid in Cth-null mice. Ishii et al. (2010) postulated that the severe myopathy in Cth-null mice may be present in unknown cases of human CTH deficiency, and noted that these patients may have hyperhomocysteinemia, which may be an independent risk factor for disease.


See Also:

Frimpter et al. (1963); Lyon et al. (1971); Scott et al. (1970); Shaw et al. (1967)

REFERENCES

  1. Espinos, C., Garcia-Cazorla, A., Martinez-Rubio, D., Martinez-Martinez, E., Vilaseca, M. A., Perez-Duenas, B., Kozich, V., Palau, F., Artuch, R. Ancient origin of the CTH alelle (sic) carrying the c.200C-T (p.T67I) variant in patients with cystathioninuria. Clin. Genet. 78: 554-559, 2010. [PubMed: 20584029] [Full Text: https://doi.org/10.1111/j.1399-0004.2010.01431.x]

  2. Frimpter, G. W., Haymovitz, A., Horwith, M. Cystathioninuria. New Eng. J. Med. 268: 333-339, 1963. [PubMed: 13959884] [Full Text: https://doi.org/10.1056/NEJM196302142680701]

  3. Frimpter, G. W. Cystathioninuria: nature of the defect. Science 149: 1095-1096, 1965. [PubMed: 5826521] [Full Text: https://doi.org/10.1126/science.149.3688.1095]

  4. Harris, H., Penrose, L. S., Thomas, D. H. H. Cystathioninuria. Ann. Hum. Genet. 23: 442-453, 1959. [PubMed: 14399948] [Full Text: https://doi.org/10.1111/j.1469-1809.1959.tb01485.x]

  5. Ishii, I., Akahoshi, N., Yamada, H., Nakano, S., Izumi, T., Suematsu, M. Cystathionine gamma-Lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury. J. Biol. Chem. 285: 26358-26368, 2010. [PubMed: 20566639] [Full Text: https://doi.org/10.1074/jbc.M110.147439]

  6. Klein, C. E., Roberts, B., Holcenberg, J., Glode, L. M. Cystathionine metabolism in neuroblastoma. Cancer 62: 291-298, 1988. [PubMed: 3383129] [Full Text: https://doi.org/10.1002/1097-0142(19880715)62:2<291::aid-cncr2820620211>3.0.co;2-q]

  7. Lemieux, B., Auray-Blais, C., Giguere, R., Shapcott, D., Scriver, C. R. Newborn urine screening experience with over one million infants in the Quebec network of genetic medicine. J. Inherit. Metab. Dis. 11: 45-55, 1988. [PubMed: 3128688] [Full Text: https://doi.org/10.1007/BF01800056]

  8. Lyon, I. C. T., Procopis, P. G., Turner, B. Cystathioninuria in a well baby population. Acta Paediat. Scand. 60: 324-328, 1971. [PubMed: 5579857] [Full Text: https://doi.org/10.1111/j.1651-2227.1971.tb06664.x]

  9. Mongeau, J.-G., Hilgartner, M., Worthen, H. G., Frimpter, G. W. Cystathioninuria: study of an infant with normal mentality, thrombocytopenia, and renal calculi. J. Pediat. 69: 1113-1120, 1966. [PubMed: 5951293] [Full Text: https://doi.org/10.1016/s0022-3476(66)80303-7]

  10. Mudd, S. H., Levy, H. L., Kraus, J. P. Disorders of Transsulfuration. In: Scriver, C. R.; Beaudet, A. L.; Sly, W. S.; Valle, D. (eds.): The Metabolic and Molecular Bases of Inherited Disease. Vol. II. (8th ed.) New York: McGraw-Hill (pub.) 2001. Pp. 2040-2043.

  11. Pascal, T. A., Gaull, G. E., Beratis, N. G., Gillam, B. M., Tallan, H. H. Cystathionase deficiency: evidence for genetic heterogeneity in primary cystathioninuria. Pediat. Res. 12: 125-133, 1978. [PubMed: 417288] [Full Text: https://doi.org/10.1203/00006450-197802000-00012]

  12. Perry, T. L., Hardwick, D. F., Hansen, S., Love, D. L., Israels, S. Cystathioninuria in two healthy siblings. New Eng. J. Med. 278: 590-592, 1968. [PubMed: 5637757] [Full Text: https://doi.org/10.1056/NEJM196803142781104]

  13. Schneiderman, L. J. Latent cystathioninuria. J. Med. Genet. 4: 260-263, 1967. [PubMed: 6082903] [Full Text: https://doi.org/10.1136/jmg.4.4.260]

  14. Scott, C. R., Dassell, S. W., Clark, S. H., Chiang-Teng, C., Swedberg, K. R. Cystathioninemia: a benign genetic condition. J. Pediat. 76: 571-577, 1970. [PubMed: 5420794] [Full Text: https://doi.org/10.1016/s0022-3476(70)80407-3]

  15. Shaw, K. N. F., Lieberman, E., Koch, R., Donnell, G. N. Cystathioninuria. Am. J. Dis. Child. 113: 119-128, 1967. [PubMed: 4289134] [Full Text: https://doi.org/10.1001/archpedi.1967.02090160169027]

  16. Tada, K., Yoshida, T., Yokoyama, Y., Sato, T., Nakagawa, H., Arakawa, T. Cystathioninuria not associated with vitamin B6 dependency: a probably new type of cystathioninuria. Tohoku J. Exp. Med. 95: 235-242, 1968. [PubMed: 5707897] [Full Text: https://doi.org/10.1620/tjem.95.235]

  17. Tadiboyina, V. T., Rupar, A., Atkison, P. Feigenbaum, A., Kronick, J., Wang, J., Hegele, R. A. Novel mutation in DGUOK in hepatocerebral mitochondrial DNA depletion syndrome associated with cystathioninuria. Am. J. Med. Genet. 135A: 289-291, 2005. [PubMed: 15887277] [Full Text: https://doi.org/10.1002/ajmg.a.30748]

  18. Wang, J., Hegele, R. A. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). Hum. Genet. 112: 404-408, 2003. [PubMed: 12574942] [Full Text: https://doi.org/10.1007/s00439-003-0906-8]

  19. Whelan, D. T., Scriver, C. R. Cystathioninuria and renal iminoglycinuria in a pedigree: a perspective on counseling. New Eng. J. Med. 278: 924-927, 1968. [PubMed: 5644557] [Full Text: https://doi.org/10.1056/NEJM196804252781702]

  20. Wilcken, B., Smith, A., Brown, D. A. Urine screening for aminoacidopathies: is it beneficial? Results of a long-term follow-up of cases detected by screening one million babies. J. Pediat. 97: 492-497, 1980. [PubMed: 7411317] [Full Text: https://doi.org/10.1016/s0022-3476(80)80216-2]

  21. Wong, L. T., Hardwick, D. F., Applegarth, D. A., Davidson, A. G. Review of metabolic screening program of Children's Hospital, Vancouver, British Columbia. Clin. Biochem. 12: 167-172, 1979. [PubMed: 519848] [Full Text: https://doi.org/10.1016/s0009-9120(79)80083-1]


Contributors:
Cassandra L. Kniffin - updated : 5/17/2012
Cassandra L. Kniffin - updated : 10/22/2010
Marla J. F. O'Neill - updated : 7/12/2005
Victor A. McKusick - updated : 3/25/2003

Creation Date:
Victor A. McKusick : 6/3/1986

Edit History:
carol : 10/28/2024
carol : 10/24/2024
alopez : 07/13/2023
carol : 08/12/2020
carol : 09/09/2016
carol : 07/09/2016
carol : 5/29/2014
terry : 5/18/2012
carol : 5/17/2012
ckniffin : 5/17/2012
wwang : 11/1/2010
ckniffin : 10/22/2010
wwang : 7/18/2005
terry : 7/12/2005
terry : 7/12/2005
terry : 5/16/2003
carol : 3/27/2003
tkritzer : 3/26/2003
terry : 3/25/2003
carol : 9/22/1999
davew : 8/26/1994
mimadm : 2/19/1994
carol : 2/4/1993
supermim : 3/16/1992
supermim : 3/20/1990
ddp : 10/26/1989